5 PM TODAY: Golden Buying Window to Ride India's Potentially Decade-Long $10 Trillion Bull Run...
Here is the latest financial fact sheet of MANKIND PHARMA. For more details, see the MANKIND PHARMA quarterly results and MANKIND PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.7 |
No. of shares | m | 400.59 |
1 Week | % | 2.1 |
1 Month | % | 6.0 |
1 Year | % | - |
52 week H/L | Rs | 2,488.7/1,240.8 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
MANKIND PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | NA | NA | |
Low | Rs | NA | NA | NA | NA | NA | |
Sales per share (Unadj.) | Rs | 124.3 | 146.6 | 155.1 | 194.3 | 218.4 | |
Earnings per share (Unadj.) | Rs | 15.2 | 26.4 | 32.3 | 36.3 | 32.7 | |
Diluted earnings per share | Rs | 15.2 | 26.4 | 32.3 | 36.3 | 32.7 | |
Cash flow per share (Unadj.) | Rs | 17.0 | 28.8 | 35.2 | 40.4 | 40.8 | |
Dividends per share (Unadj.) | Rs | 4.45 | 3.10 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 4.45 | 3.10 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 70.5 | 87.0 | 117.9 | 153.7 | 185.6 | |
Adj. book value per share | Rs | 70.5 | 87.0 | 117.9 | 153.7 | 185.6 | |
Shares outstanding (eoy) | m | 400.59 | 400.59 | 400.59 | 400.59 | 400.59 | |
Price / Sales ratio | x | 0 | 0 | 0 | 0 | 0 | |
Avg P/E ratio | x | 0 | 0 | 0 | 0 | 0 | |
P/CF ratio (eoy) | x | 0 | 0 | 0 | 0 | 0 | |
Price / Book Value ratio | x | 0 | 0 | 0 | 0 | 0 | |
Dividend payout | % | 29.2 | 11.8 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total wages/salary | Rs m | 10,948 | 13,355 | 14,158 | 16,206 | 19,185 |
MANKIND PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 49,800 | 58,719 | 62,144 | 77,816 | 87,494 | |
Other income | Rs m | 529 | 1,038 | 1,709 | 1,960 | 1,286 | |
Total revenues | Rs m | 50,329 | 59,757 | 63,854 | 79,776 | 88,780 | |
Gross profit | Rs m | 9,350 | 14,562 | 16,608 | 20,050 | 19,144 | |
Depreciation | Rs m | 690 | 991 | 1,190 | 1,666 | 3,259 | |
Interest | Rs m | 442 | 232 | 212 | 598 | 458 | |
Profit before tax | Rs m | 8,746 | 14,377 | 16,916 | 19,746 | 16,712 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,641 | 3,816 | 3,986 | 5,216 | 3,616 | |
Profit after tax | Rs m | 6,105 | 10,561 | 12,930 | 14,530 | 13,097 | |
Gross profit margin | % | 18.8 | 24.8 | 26.7 | 25.8 | 21.9 | |
Effective tax rate | % | 30.2 | 26.5 | 23.6 | 26.4 | 21.6 | |
Net profit margin | % | 12.3 | 18.0 | 20.8 | 18.7 | 15.0 |
MANKIND PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 19,431 | 28,195 | 38,796 | 44,038 | 43,246 | |
Current liabilities | Rs m | 10,241 | 12,507 | 13,534 | 26,235 | 18,631 | |
Net working cap to sales | % | 18.5 | 26.7 | 40.7 | 22.9 | 28.1 | |
Current ratio | x | 1.9 | 2.3 | 2.9 | 1.7 | 2.3 | |
Inventory Days | Days | 65 | 59 | 99 | 60 | 68 | |
Debtors Days | Days | 161 | 330 | 19 | 182 | 240 | |
Net fixed assets | Rs m | 20,854 | 22,031 | 24,170 | 47,016 | 53,578 | |
Share capital | Rs m | 401 | 401 | 401 | 401 | 401 | |
"Free" reserves | Rs m | 27,830 | 34,453 | 46,819 | 61,152 | 73,951 | |
Net worth | Rs m | 28,231 | 34,853 | 47,220 | 61,552 | 74,352 | |
Long term debt | Rs m | 251 | 582 | 577 | 492 | 231 | |
Total assets | Rs m | 40,835 | 50,253 | 63,236 | 91,085 | 96,857 | |
Interest coverage | x | 20.8 | 62.9 | 81.0 | 34.0 | 37.5 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.2 | 1.2 | 1.0 | 0.9 | 0.9 | |
Return on assets | % | 16.0 | 21.5 | 20.8 | 16.6 | 14.0 | |
Return on equity | % | 21.6 | 30.3 | 27.4 | 23.6 | 17.6 | |
Return on capital | % | 32.3 | 41.2 | 35.8 | 32.8 | 23.0 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 2.1 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 1,795 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 1,795 | |
Fx outflow | Rs m | 0 | 0 | 0 | 0 | 871 | |
Net fx | Rs m | 0 | 0 | 0 | 0 | 925 |
MANKIND PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 6,004 | 10,722 | 11,372 | 9,198 | 18,133 | |
From Investments | Rs m | -4,443 | -4,392 | -12,222 | -13,691 | -10,541 | |
From Financial Activity | Rs m | -1,751 | -5,270 | -78 | 6,046 | -7,397 | |
Net Cashflow | Rs m | -191 | 1,097 | -924 | 1,557 | 218 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Ramesh Juneja | COMP SEC: Pradeep Chugh | YEAR OF INC: 1991 | BSE CODE: 543904 | FV (Rs): 1 | DIV YIELD (%): - |
Read: MANKIND PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare MANKIND PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.